-
Blood Qian Zhijian/He Chuan cooperate to analyze the new mechanism of YTHDC1 in hematopoiesis and leukemia development
Time of Update: 2021-08-08
On July 13, 2021, Professor Qian Zhijian’s team from the University of Florida, in conjunction with Professor He Chuan’s team from the University of Chicago, published an article A Critical Role of Nuclear m6A Reader YTHDC1 in Leukemogenesis by Regulating MCM Complex-Mediated DNA Replication in Blood, using in vivo for the first time The experiment revealed the important role of YTHDC1 protein involved in normal hematopoiesis and the development of leukemia and related molecular mechanisms .
-
Big coffee talks about the progress of lymphoma treatment
Time of Update: 2021-08-08
Professor Donglu Zhao’s CAR-T cell therapy, Akilensay, was officially approved by the NMPA recently, providing a better treatment for patients with diffuse large B-cell lymphoma (DLBCL), especially for relapsed and refractory patients .
-
Consensus first, help practice, China's hemophilia A treatment enters the era of PK-guided individualized treatment
Time of Update: 2021-08-08
The release of the consensus of Chinese experts on PK guiding the treatment of hemophilia A will further promote the prevention and treatment of hemophilia A in China .
-
Express inhibits inflammation and fibrosis, FDA today approved the first ROCK2 inhibitor
Time of Update: 2021-08-08
▎The content team editor of WuXi AppTec today, Kadmon announced that the US FDA approved the company’s Rezurock (belumosudil) for the treatment of chronic graft-versus-host disease (cGVHD) patients over 12 years old.
-
BioMarin's hemophilia AAV gene therapy application is accepted by EMA
Time of Update: 2021-08-08
Recommended reading: The gene therapy for hemophilia A, which was rejected by the FDA, is now designated as an advanced therapy for regenerative medicine Yimai Meng broke the news ➤ Based on these positive effects, BioMarin regrouped and resubmitted the marketing authorization of valrox to EMA on June 25 Application (MAA) .
-
Finally waited until your first "Chinese Expert Consensus on Pharmacokinetics to Guide the Treatment of Hemophilia A" was released!
Time of Update: 2021-08-08
Recently, the Chinese Hemophilia Collaborative Group combined with relevant evidence-based medicine at home and abroad and the latest guidelines, formally issued the "Chinese Expert Consensus on Pharmacokinetics Guiding the Treatment of Hemophilia A"3, which is the clinical practice of hemophilia A in China FⅧ PK detection, interpretation and application to provide guidance .
-
Blood blockbuster: Sun Shaocong's team reveals a new mechanism for DYRK1A to regulate acute B lymphocytic leukemia
Time of Update: 2021-08-08
On July 15, 2021, Professor Sun Shaocong's research group from the Department of Immunology of MD Anderson Cancer Center in the United States published the title: DYRK1a mediates BAFF-induced noncanonical NF-κB activation to promote autoimmunity and The latest research results of B cell leukemogenesis .
-
Express is based on real-world data, FDA approves immunosuppressive agents to expand the scope of application
Time of Update: 2021-08-07
The FDA press release noted that this approval marks the first time an immunosuppressive drug has been approved to prevent rejection in adult and pediatric patients undergoing lung transplantation .
Reference materials: [1] FDA Approves New Use of Transplant Drug Based on Real-World Evidence.
-
PNH Famous Doctors Lecture Phase 3 Professor Zhang Fengkui: Treatment and follow-up of PNH
Time of Update: 2021-08-07
For patients with acute hemolytic attacks, protect important organs to avoid serious complications; for patients with long-term persistent intravascular hemolysis, due to lack of hematopoietic materials, the quality and quantity of red blood cells produced are problematic, and hematopoietic materials need to be supplemented appropriately .
-
Express for the treatment of renal anemia, 5 phase 3 clinical trials of GlaxoSmithKline's innovative therapy reached the primary endpoint
Time of Update: 2021-08-06
These trials are designed to evaluate the efficacy and safety of daprodustat in patients with anemia caused by chronic kidney disease (CKD) .
"Reference: [1] GSK announces positive headline results from five Phase 3 studies of daprodustat for patients with anaemia due to chronic kidney disease.
-
The world's leading!
Time of Update: 2021-08-06
jointly carried out the "gamma globin reactivated autologous hematopoietic stem cell transplantation for the treatment of severe β-Mediterranean "Anemia (thalassaemia) safety and effectiveness" clinical research has sent good news again, and another child bid farewell to thalassaemia through gene editing .
-
Coming soon?
Time of Update: 2021-08-05
Recent popular reports from Yimaike ★Using stem cells to rebuild "ovary", the eggs cultivated in vitro can be successfully fertilized and produce offspring. Yimai Meng broke the news. ★Half-year fi
-
Two-year follow-up data for double-antibody treatment of hemophilia A: safe and effective medical Mai Meng broke the news
Time of Update: 2021-08-05
Recommended reading: Hemophilia treatment: Roche's bispecific antibodies continue to escort, and gene therapy is the next frontier | Yimai Meng broke the news.
-
iFLT-PET/CT is an early and superior predictor of progression-free survival after chemotherapy and immunotherapy for diffuse large B-cell lymphoma
Time of Update: 2021-08-04
After a median follow-up period of 3 years, the 3-year and 5-year progression-free survival rates of patients with positive and negative PET interim scans defined using standardized contemporary assessment criteria , To determine the predicted value of iFDG-PET/CT and iFLT-PET/CT .
-
Clin Cancer Res: Long-term prognosis of relapsed/metastatic non-Hodgkin's lymphoma treated with Venetog
Time of Update: 2021-08-04
Hematological adverse events of all grades are uncommon: neutropenia (19%), anemia (19%) and blood deficiency and love are not reduced (17%), and there is no new thrombocytopenia after 2 years of treatmentIn summary, Venetog monotherapy has controllable safety and achieves durable remission in a subgroup of FL, MCL, WM and MZL patients , especially in patients who have obtained CR .
-
The new crown epidemic intensifies, and the export price of raw material heparin soars by 270%
Time of Update: 2021-08-04
The research report of Guohai Securities also pointed out that the price of heparin is mainly due to the impact of global live pig supply, but due to the impact of vaccine viruses and other factors, the recovery of the pig cycle is lower than market expectations.
-
J Thromb Haemost: Platelet count can be used as a risk factor for postpartum hemorrhage
Time of Update: 2021-08-04
Platelet count and -indices as postpartum haemorrhage risk factors: a retrospective cohort study .
15481 Original Source: Platelet -indices COUNT AS postpartum haemorrhage and Risk Factors: A Retrospective Study cohort in this message
-
J Clin Oncol: Donor-derived CD7 chimeric antigen receptor T cells for the treatment of acute T lymphocytic leukemia can be expected in the future!
Time of Update: 2021-08-04
immunityIn summary, among the 20 r/r T-ALL patients who participated in the trial, the donor-derived CD7 CAR T cells showed effective expansion, and achieved a high complete remission rate and controllable safety.
-
Blood: Prognosis and prognostic factors of angioimmunoblastic T-cell lymphoma
Time of Update: 2021-08-04
A new prognostic score (AITL score) divides The low-, medium-, and high-risk subgroups correspond to the 5-year OS estimates of 63%, 54%, and 21%, respectivelyOS and PFS in patients with or without POD24OS and PFS in patients with or without POD24Finally, POD24 is a powerful prognostic factor.
-
J Hematol Oncol: PD-1 monoclonal antibody---the efficacy and safety of geptanolimab injection (geptanolimab) in peripheral T-cell lymphoma (PTCL)
Time of Update: 2021-08-03
The study showed that geptanolimab injection (geptanolimab) has a significant effect in the treatment of patients with relapsed or refractory PTCL: the ORR assessed by IRC is 36.
